Outcomes for Recurrent Mantle Cell Lymphoma Post-Ibrutinib Therapy: A Retrospective Cohort Study from a Japanese Administrative Database

Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388(10044):565–75.

CAS  PubMed  Article  Google Scholar 

Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017;377(13):1250–60.

PubMed  Article  Google Scholar 

Zoellner AK, Unterhalt M, Stilgenbauer S, Hübel K, Thieblemont C, Metzner B, et al. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2021;8(9):e648–57.

PubMed  Article  Google Scholar 

Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005;105(7):2677–84.

CAS  PubMed  Article  Google Scholar 

Ogura M, Yamamoto K, Morishima Y, Wakabayashi M, Tobinai K, Ando K, et al. R-High-CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY. Cancer Sci. 2018;109(9):2830–40.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Eskelund CW, Kolstad A, Jerkeman M, Räty R, Laurell A, Eloranta S, et al. 15-year follow-up of the second nordic mantle cell lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol. 2016;175(3):410–8.

CAS  PubMed  Article  Google Scholar 

Wiestner A. Targeting B-Cell receptor signaling for anticancer therapy: the Bruton’s tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J Clin Oncol. 2013;31(1):128–30.

CAS  PubMed  Article  Google Scholar 

Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. J Clin Invest. 2012;122(10):3416–23.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Young RM, Staudt LM. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov. 2013;12(3):229–43.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Buggy JJ, Elias L. Bruton tyrosine kinase (BTK) and its role in B-cell malignancy. Int Rev Immunol. 2012;31(2):119–32.

CAS  PubMed  Article  Google Scholar 

Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–16.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Rule S, Dreyling M, Goy A, Hess G, Auer R, Kahl B, et al. Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. Haematologica. 2019;104(5):e211-e4.

Rule S, Dreyling M, Goy A, Hess G, Auer R, Kahl B, et al. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies. Br J Haematol. 2017;179(3):430–8.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016;127(12):1559–63.

CAS  PubMed  Article  Google Scholar 

Jain P, Kanagal-Shamanna R, Zhang S, Ahmed M, Ghorab A, Zhang L, et al. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol. 2018;183(4):578–87.

CAS  PubMed  Article  Google Scholar 

Epperla N, Hamadani M, Cashen AF, Ahn KW, Oak E, Kanate AS, et al. Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a “real world” study. Hematol Oncol. 2017;35(4):528–35.

CAS  PubMed  Article  Google Scholar 

Shah B, Zhao X, Silva AS, Shain KH, Tao J. Resistance to Ibrutinib in B cell malignancies: one size does not fit all. Trends Cancer. 2018;4(3):197–206.

CAS  PubMed  Article  Google Scholar 

Roué G, Sola B. Management of drug resistance in mantle cell lymphoma. Cancers (Basel). 2020;12(6):1565.

Article  CAS  Google Scholar 

Hershkovitz-Rokah O, Pulver D, Lenz G, Shpilberg O. Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects. Br J Haematol. 2018;181(3):306–19.

CAS  PubMed  Article  Google Scholar 

George B, Chowdhury SM, Hart A, Sircar A, Singh SK, Nath UK, et al. Ibrutinib resistance mechanisms and treatment strategies for B-cell lymphomas. Cancers (Basel). 2020;12(5).

Cheah CY, Chihara D, Romaguera JE, Fowler NH, Seymour JF, Hagemeister FB, et al. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol. 2015;26(6):1175–9.

CAS  PubMed  Article  Google Scholar 

Weaver JA, Peng Y, Ji Y, Gilbertson D, Pease DF, Morrison VA. A medicare database analysis of practice patterns in patients with mantle cell lymphoma. J Geriatr Oncol. 2021;12(6):894–901.

CAS  PubMed  Article  Google Scholar 

Goyal RK, Jain P, Nagar SP, Le H, Kabadi SM, Davis K, et al. Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma. Leuk Lymphoma. 2021;62(6):1325–34.

CAS  PubMed  Article  Google Scholar 

Sharman J, Kabadi SM, Clark J, Andorsky D. Treatment patterns and outcomes among mantle cell lymphoma patients treated with ibrutinib in the United States: a retrospective electronic medical record database and chart review study. Br J Haematol. 2021;192(4):737–46.

CAS  PubMed  Article  Google Scholar 

Izutsu K, Suzumiya J, Takizawa J, Fukase K, Nakamura M, Jinushi M, et al. Real world treatment practices for mantle cell lymphoma in Japan: an observational database research study (CLIMBER-DBR). J Clin Exp Hematop. 2021;61(3):135–44.

PubMed  PubMed Central  Article  Google Scholar 

Wade DT, Collin C. The Barthel ADL Index: a standard measure of physical disability? Int Disabil Stud. 1988;10(2):64–7.

CAS  PubMed  Article  Google Scholar 

Okamoto M, Kusumoto S. JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-4. Mantle cell lymphoma (MCL). Int J Hematol. 2020;111(1):5–15.

Zelenetz AD, Gordon LI, Chang JE, et al. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021. J Natl Compr Canc Netw. 2021;19(11):1218–1230.

Article  Google Scholar 

Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–9.

PubMed  Article  Google Scholar 

Paydas S. Management of adverse effects/toxicity of ibrutinib. Crit Rev Oncol Hematol. 2019;136:56–63.

PubMed  Article  Google Scholar 

National Comprehensive Cancer Network (NCCN) Guidelines for Patients. Mantle Cell Lymhoma. 2021. Available at https://www.nccn.org/patients/guidelines/content/PDF/Mantle-patient-guideline.pdf.

Kabadi SM, Near A, Wada K, Burudpakdee C. Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States. Cancer Med. 2019;8(17):7174–85.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Sharman J, Kabadi SM, Clark J, Andorsky D. Treatment patterns and outcomes among mantle cell lymphoma patients treated with ibrutinib in the United States: a retrospective electronic medical record database and chart review study. Br J Haematol. 2021;192(4):737–46.

CAS  PubMed  Article  Google Scholar 

Ghosh N, Emond B, Lafeuille MH, Côté-Sergent A, Lefebvre P, Huang Q. Treatment patterns among patients with mantle cell lymphoma and comparison of healthcare resource utilization and costs among relapsed/refractory patients treated with ibrutinib or chemoimmunotherapy: a real-world retrospective study. Clin Ther. 2021;43(8):1285–99.

CAS  PubMed  Article  Google Scholar 

McCulloch R, Lewis D, Crosbie N, Eyre TA, Bolam S, Arasaretnam A, et al. Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients. Br J Haematol. 2021;193(2):290–8.

CAS  PubMed  Article  Google Scholar 

Abrahamsson A, Albertsson-Lindblad A, Brown PN, Baumgartner-Wennerholm S, Pedersen LM, D’Amore F, et al. Real world data on primary treatment for mantle cell lymphoma: a nordic lymphoma group observational study. Blood. 2014;124(8):1288–95.

CAS  PubMed  Article  Google Scholar 

Pfreundschuh M. Age and sex in non-hodgkin lymphoma therapy: it’s not all created equal, or is it? Am Soc Clin Oncol Educ Book. 2017;37:505–11.

PubMed  Article  Google Scholar 

Karmali R, Switchenko JM, Goyal S, Shanmugasundaram K, Churnetski MC, Kolla B, et al. Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. Am J Hematol. 2021;96(11):1374–84.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Rampotas A, Wilson MR, Lomas O, Denny N, Leary H, Ferguson G, et al. Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: a UK and Ireland analysis. Br J Haematol. 2021;194(2):365–77.

CAS 

留言 (0)

沒有登入
gif